Focused On-demand Library for THO complex subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96FV9

UPID:

THOC1_HUMAN

Alternative names:

Nuclear matrix protein p84; hTREX84

Alternative UPACC:

Q96FV9; B2RBP6; Q15219; Q64I72; Q64I73

Background:

THO complex subunit 1, also known as Nuclear matrix protein p84 or hTREX84, plays a crucial role in RNA metabolism. It is involved in the export of polyadenylated RNA, mRNA transcription, processing, and nuclear export. The protein is a component of the TREX complex, essential for mRNA export via the TAP/NFX1 pathway and plays a role in genome stability by preventing R-loop formation. Additionally, it participates in an apoptotic pathway characterized by caspase-6 activation and is implicated in cell cycle regulation.

Therapeutic significance:

Given its involvement in RNA metabolism and apoptotic pathways, THO complex subunit 1 holds potential in therapeutic strategies targeting genetic disorders and cancer. Its role in the progressive, bilateral hearing loss condition, Deafness, autosomal dominant, 86, underscores its clinical relevance. Understanding the protein's function could pave the way for innovative treatments for hearing loss and other related conditions.